Curriculum vitae of HDAC6 in solid tumors

Area of Science:

• Biochemistry
• Oncology
• Immunology

Background:

• Histone deacetylase 6 (HDAC6) is a unique cytoplasmic enzyme with dual catalytic and ubiquitin-binding domains.
• HDAC6 is overexpressed in solid tumors, regulating key pathways like hormone receptors and p53 signaling.
• HDAC6 promotes tumor progression, invasion, metastasis, drug resistance, and immune evasion, acting as an oncogenic factor.

Purpose of the Study:

• To review the structure, biological functions, and mechanisms of HDAC6 in solid tumors and the immune system.
• To discuss preclinical and clinical trials of selective HDAC6 inhibitors for cancer therapy.

Main Methods:

• Literature review of HDAC6 structure, function, and involvement in carcinogenesis.
• Analysis of preclinical and clinical data on selective HDAC6 inhibitors.
• Examination of HDAC6's role in tumor cell biology and the tumor immune microenvironment.

Main Results:

• HDAC6 plays a critical role in promoting solid tumor growth, metastasis, and immune suppression.
• Unlike broad-spectrum HDAC inhibitors, HDAC6 inhibition shows minimal toxicity to normal cells.
• Selective HDAC6 inhibitors demonstrate potential as effective monotherapies or in combination treatments.

Conclusions:

• Targeting HDAC6 is a promising therapeutic strategy for solid tumors.
• Selective HDAC6 inhibition offers a targeted approach to cancer treatment with a favorable safety profile.
• HDAC6 inhibitors can enhance anti-tumor immunity, leading to improved patient outcomes.